JAMA Review Time

For year-over-year citation metrics data, see the jama citation metric page.

JAMA held flat at 65.4 from 2023 to 2024 after the pandemic citation spike fully normalized. That steady year-over-year picture matters because it shows the flagship is back on its structural baseline rather than drifting downward in general medicine.

JAMA requires a structured abstract with specific sections (Importance, Objective, Design, Setting, Participants, Interventions or Exposures, Main Outcomes and Measures, Results, Conclusions and Relevance). Editors use this structure to triage. If the structured abstract doesn't work, the paper doesn't get read further.

JAMA's instructions ask authors to describe statistical methods in enough detail to reproduce the results, to report uncertainty, and to identify primary outcomes before the study began. JAMA does not publish whether a separate statistical review is added to peer review, so don't plan your timeline around one.

JAMA sits atop a network of specialty journals (JAMA Oncology, JAMA Cardiology, JAMA Internal Medicine, JAMA Neurology, etc.). Authors can preselect referral at submission, so a paper that has merit but isn't broad enough for the flagship can be referred within the network, with reviewers' comments if available, which can speed up the process at the receiving journal.

Fast editorial decision (median 2 days): A clinical question that isn't broad enough for JAMA's general physician readership can end here.

Referral to a Network journal (if you preselected it): The editors think the work fits a JAMA Network specialty journal better. Take this seriously. JAMA Oncology, JAMA Cardiology, and JAMA Internal Medicine are top-tier journals in their own right.

Review with external peer review (median 24 days): JAMA's published median to a first decision when a manuscript goes to external review.

Revision requiring AMA citation style corrections: Common for authors unfamiliar with JAMA's specific formatting requirements. AMA style from day one saves a revision round.

If the status still reads With Editor, the paper has not left triage yet; our JAMA "With Editor" guide explains what the deputy editor is deciding during that screen.

JAMA timing is only one piece of the editorial reality. The harder question is usually whether the paper belongs in the flagship or whether a JAMA Network specialty journal would be the cleaner fit from the start. That distinction matters because the same review window can either represent serious all-of-medicine scrutiny or unnecessary delay for a paper that was always specialty-specific.

For authors, that is the practical lesson behind the timeline. A slower flagship process is often worth it only when the manuscript really has general clinical reach. If the true audience is oncology, neurology, cardiology, or pediatrics, the extra weeks can be a sign that the paper is being tested against a broader readership than it actually needs.

At JAMA, time in review often reflects breadth testing more than pure methodological delay. Reviewers and editors are asking whether the study changes practice outside one specialty and whether non-specialist physicians can understand why the result matters. That makes the waiting period more informative than many authors realize. A paper that is scientifically strong but framed too narrowly may still survive peer review, but the process often becomes slower because editors are trying to decide whether the flagship audience is genuinely right.

That is why the most useful preparation during the wait is not generic rebuttal drafting. It is clarifying the paper's broad clinical sentence: what a general physician should do differently, what kind of patient or care setting is affected, and why this is not merely a subspecialty update. If that sentence is weak, the review timeline is telling you something important about target fit.

Use the timeline together with the surrounding cluster, not in isolation:

• JAMA submission guide

• JAMA submission process

• JAMA citation metric

• JAMA pre-submission checklist

• JAMA under review

• How to clear desk review at JAMA

• Is JAMA a good journal?

For JAMA-targeted manuscripts, three patterns most consistently predict slow review at JAMA (Journal of the American Medical Association). Of manuscripts we screened in 2025 targeting JAMA and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: JAMA editors apply practice-relevance threshold during desk-screen; mechanism-only papers without clinical-application pathway get rejected within 7 days.

Scope-fit ambiguity in the abstract. JAMA editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (clinical research with practice-relevant implications for US-based physicians). The named failure pattern: mechanism-only papers without clinical-application pathway get desk-rejected within 7 days. Check whether your abstract reads to JAMA's scope →

Methods package incomplete for the journal's reviewer pool. JAMA reviewers expect specific methodological detail. Trials with pre-specified primary endpoint not matching the headline finding extend revision rounds. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. JAMA's instructions tell authors to check all references for completeness, accuracy, and integrity. Check whether your reference list is clean against Crossref + Retraction Watch →

Published JAMA review-time medians mask real variation. Manuscripts that editors decide without external review pull the first-decision median down; papers that enter full peer review experience longer waits than the 2-day median suggests, and JAMA publishes the with-review median (24 days) separately. JAMA also publishes acceptance-to-online-first time (39 days for research manuscripts) as a separate figure.

A JAMA desk-rejection risk check scores fit against the journal's editorial bar.